Drug Trial Radar · NCT06364072
Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients
Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
May 27, 2024
Primary completion
May 9, 2025
Study completion May 9, 2025
Sponsor
- Lead sponsor
- Cessatech A/SIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an acute care (i.e. emergency) setting. The study is a part of the clinical development plan for the development of CT001 nasal spray for treatment of acute pain in children.
Conditions
- Pain
Interventions
CT001Drug
Intranasal
Primary outcomes
What the sponsor says the trial is designed to measure.
- SedationTime frame: At baseline and 10, 15, 20, 30, 45 and 60 min after first IMP administration. If a second IMP dose was needed, sedation score was performed at the timepoints relative to first IMP administration.
- Respiratory DepressionTime frame: At baseline and 10, 15, 20, 25, 30, 35, 45, 60 and 75 min after IMP administration.
- Peripheral Oxygen SaturationTime frame: At baseline and 10, 15, 20, 25, 30, 35, 45, 60 and 75 min after IMP administration.
- Cardiovascular StabilityTime frame: At baseline and 10, 15, 20, 25, 30, 35, 45, 60 and 75 min after IMP administration.
- Number of Reported Adverse EventsTime frame: Through study completion; up to 7 days
- Number of Adverse Events (AEs) Reported Per ParticipantTime frame: Through study completion; up to 7 days
- Local Nasal IrritationTime frame: 30 and 60 min post IMP administration
- Analgesic EffectTime frame: At baseline and at 15 and 30 min post first IMP dose
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Hospital General Universitario Dr. Balmis
Alicante, Spain
Hospital Sant Joan de Deu
Barcelona, Spain
Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz (HULP) -
Madrid, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, Spain
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
Royal London Hospital
London, United Kingdom
Sheffield Children's Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.